|
AKAP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.85869996960753E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.19470000453848E-08 |
| Normal-vs-Stage2 |
5.382100E-03 |
| Normal-vs-Stage3 |
9.56519999872896E-08 |
| Normal-vs-Stage4 |
4.39670000407233E-09 |
| Stage1-vs-Stage2 |
1.758180E-01 |
| Stage1-vs-Stage3 |
3.467600E-01 |
| Stage1-vs-Stage4 |
2.157000E-01 |
| Stage2-vs-Stage3 |
5.850300E-02 |
| Stage2-vs-Stage4 |
4.189800E-02 |
| Stage3-vs-Stage4 |
8.651400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.36160005282227E-10 |
| Normal-vs-AfricanAmerican |
2.802100E-03 |
| Normal-vs-Asian |
2.399200E-04 |
| Caucasian-vs-AfricanAmerican |
2.751800E-01 |
| Caucasian-vs-Asian |
3.134000E-01 |
| AfricanAmerican-vs-Asian |
7.970200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.52409981804647E-10 |
| Normal-vs-Female |
3.58670000366601E-08 |
| Male-vs-Female |
1.817170E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.18559999995327E-06 |
| Normal-vs-Age(41-60Yrs) |
7.0734529344918E-12 |
| Normal-vs-Age(61-80Yrs) |
6.30169999999985E-05 |
| Normal-vs-Age(81-100Yrs) |
4.352100E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.674150E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.221000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.309800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.152750E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.760400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.551600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.482400E-03 |
| Classical-VS-Follicular |
7.664400E-03 |
| Classical-VS-Other |
8.607600E-01 |
| Classical-VS-Normal |
5.31830024463886E-10 |
| Tall-VS-Follicular |
7.66140000000304E-05 |
| Tall-VS-Other |
3.583600E-01 |
| Tall-VS-Normal |
3.20632409511745E-12 |
| Follicular-VS-Other |
4.707600E-01 |
| Follicular-VS-Normal |
3.708100E-02 |
| Other-VS-Normal |
1.858260E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.58362000000078E-05 |
| Normal-vs-N1 |
1.2208000166325E-09 |
| N0-vs-N1 |
1.028230E-02 |
|
|
